Annals of Thoracic Medicine
ORIGINAL ARTICLE
Year
: 2012  |  Volume : 7  |  Issue : 3  |  Page : 130--132

MMP1-1607(1G>2G) polymorphism and the risk of lung cancer in Lebanon


Hana Fakhoury1, Sara Noureddine2, Hania N Chmaisse3, Hani Tamim4, Rajaa F Makki5 
1 Department of Basic Sciences, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
2 Department of Biological and Environmental Sciences, Faculty of Science, American University of Beirut Medical Center, Beirut, Lebanon
3 Department of Pharmacology, Faculty of Pharmacy, American University of Beirut Medical Center, Beirut, Lebanon
4 Department of Internal Medicine, Clinical Research Institute, American University of Beirut Medical Center, Beirut, Lebanon
5 Department of Biological and Environmental Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon

Correspondence Address:
Hana Fakhoury
Department of Basic Sciences, University Pre-Professional Program, King Saud bin Abdulaziz University for Health Sciences, Riyadh
Saudi Arabia

Context: Matrix metalloproteinases (MMPs) are a family of enzymes that degrade various components of the extracellular matrix and are involved in the development and progression of cancer. Lung cancer is the most commonly diagnosed cancer in Lebanon. MMP1 is responsible for degrading stromal collagens, which enhance the ability of neoplastic cells to cross basal membrane of both the endothelium and the vascular endothelium. A recent meta-analysis has suggested that the MMP1-1607 2G allele may be associated with an increased risk for certain types of cancers. Aim: This study was undertaken to investigate the association between guanine insertion polymorphism in the MMP1 promoter and the susceptibility to lung cancer in the Lebanese population. Settings and Design: This case-control study was conducted on 41 patients with lung cancer and 51 age-matched healthy controls, recruited from different regions of Lebanon. Methods: Cases were histologically confirmed lung cancer patients obtained from different hospitals in Lebanon. Controls were healthy unrelated individuals with no history of cancer or genetic diseases. All subjects were genotyped for MMP1 -1607(1G>2G) polymorphism using polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). Results: No statistically significant differences were found when genotype and allele distribution of MMP1 -1607(1G>2G) polymorphism were compared between patients with lung cancer and controls [P= 0.6 by chi-squared test on a 3x2 contingency table; allelic P=0.61, OR (95% CI) = 1.18 (0.60-2.31)]. Conclusion: Our data shows that MMP1 promoter polymorphism is not associated with lung cancer susceptibility in the Lebanese population.


How to cite this article:
Fakhoury H, Noureddine S, Chmaisse HN, Tamim H, Makki RF. MMP1-1607(1G>2G) polymorphism and the risk of lung cancer in Lebanon.Ann Thorac Med 2012;7:130-132


How to cite this URL:
Fakhoury H, Noureddine S, Chmaisse HN, Tamim H, Makki RF. MMP1-1607(1G>2G) polymorphism and the risk of lung cancer in Lebanon. Ann Thorac Med [serial online] 2012 [cited 2020 Sep 18 ];7:130-132
Available from: http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2012;volume=7;issue=3;spage=130;epage=132;aulast=Fakhoury;type=0